Raymond James Financial, Inc. (RJF)

Inozyme Pharma Revenue

Raymond James Financial had revenue of $3.38B in the quarter ending June 30, 2025, with 4.83% growth. This brings the company's revenue in the last twelve months to $13.77B, up 11.78% year-over-year. In the fiscal year ending September 30, 2024, Raymond James Financial had annual revenue of $12.80B with 11.18% growth.

• Revenue (ttm): $13.77B
• Revenue Growth: +11.78%
• P/S Ratio: 2.44
• Revenue / Employee: $724,789
• Employees: 19,000
• Market Cap: 32.88B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Sep 30, 2024	12.80B	1.29B	11.18%
Sep 30, 2023	11.51B	683.00M	6.31%
Sep 30, 2022	10.83B	1.01B	10.33%
Sep 30, 2021	9.81B	2.06B	26.51%
Sep 30, 2020	7.76B	64.00M	0.83%

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.